Clinical Scorecard: Thrombotic Microangiopathy Associated with Carfilzomib Treatment: A Case Series from Singapore
At a Glance
Category
Detail
Condition
Thrombotic microangiopathy (TMA) associated with carfilzomib treatment
Key Mechanisms
Carfilzomib is an irreversible proteasome inhibitor; TMA may be related to drug toxicity and concurrent viral infections; absence of hypertension and proteinuria suggests non-VEGF inhibition mechanism
Target Population
Patients with multiple myeloma receiving carfilzomib, including newly diagnosed and relapsed cases
Care Setting
Tertiary hospitals with hematology/oncology services
Key Highlights
Four cases of TMA identified among 24 patients treated with carfilzomib (16.7% incidence) in Singapore tertiary centers.
TMA occurred at carfilzomib doses of 27 mg/m2 and 56 mg/m2, with onset typically during the second or third treatment cycle.
Management included discontinuation of carfilzomib, supportive care, temporary hemodialysis in some cases, and no rechallenge with carfilzomib.
Guideline-Based Recommendations
Diagnosis
Monitor for anemia, thrombocytopenia, schistocytes on blood film, and acute kidney injury during carfilzomib treatment.
Perform hemolytic screen including LDH, bilirubin, reticulocyte index, haptoglobin, and Coomb’s test.
Assess ADAMTS13 activity to exclude thrombotic thrombocytopenic purpura.
Rule out infections and coagulopathy.
Management
Discontinue carfilzomib immediately upon diagnosis of TMA.
Provide supportive care including transfusions and renal replacement therapy as needed.
Consider plasmapheresis if clinically indicated, though some cases recover without it.
Avoid rechallenge with carfilzomib after TMA resolution.
Monitoring & Follow-up
Regular monitoring of blood counts and renal function during carfilzomib therapy.
Close observation for signs of hemolysis and renal impairment, especially during early treatment cycles.
Risks
Potential for serious hematologic adverse events including anemia, thrombocytopenia, and acute kidney injury.
Risk of TMA may be increased with concurrent viral infections.
Patient & Prescribing Data
Multiple myeloma patients treated with carfilzomib, including frontline and relapsed settings.
TMA can occur at standard dosing regimens; early recognition and cessation of carfilzomib leads to recovery in most cases; no further carfilzomib use recommended after TMA.
Clinical Best Practices
Initiate carfilzomib only in patients with adequate baseline renal function and platelet counts.
Educate patients to report symptoms such as fever, fatigue, or decreased urine output promptly.
Investigate and manage concurrent infections aggressively to reduce TMA risk.
Use alternative myeloma therapies post-TMA resolution to avoid recurrence.
by Y Chen, M Ooi, S F Lim, A Lin, J Lee, C Nagarajan, C Phipps, Y S Lee, N F Grigoropoulos, Z Lao, S Surendran, E M Teh, Y T Goh, W J Chng, S K Gopalakrishnan
